Low dose cyclophosphamide

Phase 1Small molecule

BBriaCell Therapeutics Corporation

Low dose cyclophosphamide is one of 78 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Ovarian CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

33 2

Tecentriq

Roche

Phase 3

31 3

Yervoy

Bristol-Myers Squibb

Phase 3

11 4

Taxotere

AAvyxa

Phase 3

23 5

Imjudo

AstraZeneca

Phase 3

5 6

Trodelvy

Gilead

Phase 3

1 7

Oncovin

EEastern Cooperative Oncology Group

Phase 3

3 8

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

3 9

Tiragolumab

Roche

Phase 3

3 10

MEDI4736

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Small Cell Lung Cancer

NCT05195619

Clinical

Trials by Indication[1]

Peritoneal Cancer1 trial

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Completed·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 1·NCT01416038·19 enrolled

High Risk1 trial

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03417154·12 enrolled

Small Cell Lung Cancer1 trial

Personalized DC Vaccines in Non Small Cell Lung Cancer

Active, not recruiting·—·Phase 1·NCT05195619·16 enrolled

Ovarian Carcinoma1 trial

PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma

Withdrawn·—·Phase 1/2·NCT05714306

Unspecified1 trial

Combination Study of SV-BR-1-GM With Retifanlimab

Enrolling by invitation·BBriaCell Therapeutics Corporation·Phase 1/2·NCT03328026·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Low dose cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low dose cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low dose cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BriaCell Therapeutics Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBriaCell Therapeutics Corporation

Low dose cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Peritoneal Cancer1 trial

High Risk1 trial

Small Cell Lung Cancer1 trial

Ovarian Carcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News